Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperlipoproteinemia Clear all
Completed Phase 4 Interventional Results available

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

NCT05742841
View directory record Official record
Conditions
Lipid Disorder
Interventions
moderate- or high-intensity statin/ rosuvastatin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons

NCT00194428
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X, Hyperlipidemia, Hypertension
Interventions
Almond enriched diet, Low fat caloric diet
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction

NCT00203476
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia
Interventions
Niacin, Colestipol, Ezetimibe
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults

NCT00955903
View directory record Official record
Conditions
Obesity, Diabetes, Hypertension, Hyperlipidemia
Interventions
Exercise, Reduced Calorie Diet, Weight Maintenance Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 10, 2026, 6:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 10, 2026, 6:19 PM EDT
Recruiting Not applicable Interventional

Preventative Screening and Health Coaching in a Food Insecure Population

NCT06907524
View directory record Official record
Conditions
Cardiovascular Disease Prevention, Cardiometabolic Diseases, Cardiovascular Risk Factor, Cardiovascular Risk Score, Hypertension, Hyperlipidemia, Diabetes, Lifestyle Modification, Health Coaching
Interventions
Longitudinal, Individualized Health Coaching
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

NCT03067441
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism

NCT02366156
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Low Dose Grape Blend, High Dose Grape Blend
Dietary Supplement
Lead sponsor
Access Business Group
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Not applicable Interventional

Controlling Hypertension in Diabetes- Feasibility Study

NCT01145742
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Hyperlipidemia
Interventions
home health/primary care collaboration
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 10, 2026, 6:19 PM EDT
Enrolling by invitation Not applicable Interventional

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

NCT05284513
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
FH diagnosis program, Implementation strategy package: Develop and implement tools for quality monitoring, Implementation strategy package: Develop educational materials, Implementation strategy package: Conduct educational outreach visits, Implementation strategy package: Intervene with clinicians and patients to enhance, Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions, Implementation strategy package: Audit and provide feedback, Implementation strategy package: Stage implementation scale up
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
26 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Multiple Locations, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 4 Interventional

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

NCT00754039
View directory record Official record
Conditions
Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions
colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
30 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 10, 2026, 6:19 PM EDT
Recruiting No phase listed Observational

HoFH, the International Clinical Collaborators Registry

NCT04815005
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation

NCT00123214
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Controlled Dietary Intervention
Drug
Lead sponsor
St. Vincent's Medical Center
Other
Eligibility
25 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2006 · Synced Oct 10, 2026, 6:19 PM EDT
Not listed No phase listed Observational

School-based Education and Screening Program With Lipid Screening as a Means to Identify Familial Hyperlipidemia

NCT05767996
View directory record Official record
Conditions
Familial Hyperlipidemia
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
6 Years to 10 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Not applicable Interventional

Improving Heart Health in Appalachia

NCT01884246
View directory record Official record
Conditions
Obesity, Hypertension, Hyperlipidemia, Depression
Interventions
Self-care CVD risk reduction, Referral to primary care provider for CVD risk management
Behavioral · Other
Lead sponsor
Debra Moser
Other
Eligibility
21 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 10, 2026, 6:19 PM EDT
Completed No phase listed Observational

Equitable Implementation of Cascade Screening for Familial Hypercholesterolemia

NCT05430191
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Cascade Screening
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 10, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

NCT00145431
View directory record Official record
Conditions
Hyperlipoproteinemia Type III
Interventions
torcetrapib/atorvastatin, atorvastatin, fenofibrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Anaheim, California • Huntington Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients

NCT00569959
View directory record Official record
Conditions
Diabetes Mellitus, Normal Glucose Metabolism, Hyperlipidemia
Interventions
fasting 12+ hours, Non-fasting
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 10, 2026, 6:19 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

NCT07592858
View directory record Official record
Conditions
PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louisville, Kentucky • Augusta, Maine
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

NCT05425745
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions
Obicetrapib, Placebo
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 10, 2026, 6:19 PM EDT
Completed No phase listed Observational

Genetic Influences on Statin Blood Concentrations in African Americans

NCT01569867
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 10, 2026, 6:19 PM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

NCT02670434
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
NK-104-CR, Placebo, Livalo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
45
States / cities
Beverly Hills, California • Chino, California • Lincoln, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 10, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

NCT01912560
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
CAT-2003, Placebo, Statin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 10, 2026, 6:19 PM EDT